Patterns of antihypertensive drug utilization in primary care by Pittrow, David et al.
Patterns of antihypertensive drug utilization in primary care 
 
D. Pittrow, W. Kirch, P. Bramlage, H. Lehnert, M. Höfler,  T. Unger,  A. M. Sharma,  H.-U. 
Wittchen 
 
 
   
Abstract  
Background: In the treatment of hypertension, physicians’ attitudes and practice patterns are receiving 
increased attention as contributors to poor blood pressure (BP) control. Thus, current use of 
antihypertensive drugs in primary care was analyzed and the association with selected physician and 
patient characteristics was assessed.  
Methods: The Hypertension and Diabetes Risk Screening and Awareness (HYDRA) study is a cross-
sectional point prevalence study of 45,125 primary care attendees recruited from a representative 
nationwide sample of 1912 primary care practices in Germany. Prescription frequencies of the various 
antihypertensive drugs in the individual patients were recorded by the physicians using standardized 
questionnaires. We assessed the association of patient variables [age, gender; co-morbidities such as 
diabetes, nephropathy or coronary heart disease (CHD)] and physician variables (general practitioner 
vs internist, guideline adherence, etc.) with drug treatment intensity and prescription patterns.  
Results: Of all 43,549 patients for whom a physician diagnosis on hypertension or diabetes was 
available, 17,485 (40.1%) had hypertension. Of these hypertensive patients, 1647 (9.4%) received no 
treatment at all, 1191 (6.8%) received non-pharmacological measures only, and 14,647 (83.8%) were 
given one or more antihypertensive drugs. Drug treatment rates were lower in young patients (16–40 
years: 57.4%). BP control was poor: 70.6% of all patients were not normalized, i.e., had BP ≥140/90 
mmHg. Antihypertensive treatment was generally intensified with increasing age, or if complications 
or comorbidities were present. The use of the different drug classes was rather uniform across the 
various patient subgroups (e.g., by age and gender). Individualized treatment with regard to co-
morbidities as recommended in guidelines was not the rule. Adherence to guidelines as self-reported 
by physicians as well as other physician characteristics (region, training etc.) did not result in more 
differentiated prescription pattern.  
Conclusions: Despite the broad armamentarium of drug treatment options, physicians in primary care 
did not treat hypertension aggressively enough. Treatment was only intensified at a late stage, after 
complications had occurred. Treatment should be more differentiated in terms of coexisting 
morbidities such as diabetes, nephropathy, or CHD. 
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Introduction 
 
Hypertension is among the leading reasons for office visits in primary care [1, 2] and its 
treatment is sometimes even regarded as a barometer for the general quality of healthcare 
systems [3]. Despite the undisputed importance to treat hypertension aggressively, control 
rates are still unsatisfactory [4, 5]. This holds especially true for the general population in 
Europe compared with the US, with Germany having the least favourable outcome [6]. At the 
same time, the new JNC-VII guidelines propose even lower BP targets, defining patients with 
BP values of 120–139/80–89 mmHg as pre-hypertensive requiring lifestyle modification [5]. 
Along with such data, there is growing evidence now that uncontrolled hypertension also 
occurs in populations with good access to health care [7, 8].  
Efforts to effectively improve the extent of control of hypertension should ideally be based on 
a thorough understanding of the characteristics of patients, the dynamics of the health care 
system and, most importantly, on the work and function of the primary care physician as the 
gatekeeper [9]. Therefore, the role of physicians’ attitudes and practice patterns (recognition, 
treatment, and management) has received increased attention as a contributor to poor control 
of hypertension [3, 10, 11]. Within this search, an important, but obviously largely neglected, 
aspect is the choice and intensity of antihypertensive medication treatments in routine care. 
To our knowledge, there are no major drug utilization studies that directly link the patient’s 
diagnoses to actual treatment patterns in unselected primary care samples.  
In an attempt to provide such data, we analyzed recent cross-sectional data from the 
Hypertension and Diabetes Risk Screening and Awareness Study (HYDRA) to address the 
following questions: (1) Which antihypertensive drug classes and combinations, respectively, 
are applied by general physicians in patients with hypertension? (2) Do drug treatments differ 
with respect to certain patient characteristics such as age, gender, and frequent concomitant 
diseases such as diabetes mellitus, nephropathy, or coronary heart disease (CHD), since these 
patients are considered to be at particularly high cardiovascular risk? (3) Are certain physician 
variables, such as type of medical training, regional setting or others, associated with 
differences in drug treatment?  
 
 
Methods 
 
Study design 
 
HYDRA was a cross-sectional point prevalence study. It was based on a two-step 
observational epidemiological design (Fig. 1). A nationwide sample of doctors with primary 
care functions (medical practitioners, generalists, general internists) was drawn on the basis of 
1060 regional segments [according to the criteria of the Institute for Medical Statistics (IMS), 
Frankfurt am Main, Germany], clustered into geographical areas for which primary care 
doctor addresses were available [12]. In step 1, n=2416 of these physicians were asked to 
complete a prestudy questionnaire [response rate n=1912 (79.1%)] to describe personal and 
structural characteristics of each practice and to assess self-perceived qualifications and 
attitudes related to recognition, diagnosis, and care of patients. Step 2 was an assessment (half 
day on 18 or 20 September 2001) of all patients attending doctors’ offices on this day. 
Patients were informed by posters and leaflets about participation of the respective practices 
in the study and they were free to decline participation. The following exclusion criteria 
applied: age below 16 years, acute medical condition making the screening procedure 
unacceptable on ethical grounds, dementia or other cognitive or sensory deficits that would 
make it unlikely that the self-reported measures could be completed or would provide 
meaningful information. Oral informed consent was obtained from all patients. Importantly, 
physicians were instructed not to change their routine-practice behaviors nor to selectively 
invite patients for participation. Patients completed a self-report patient questionnaire, 
followed by a structured doctor’s clinical appraisal, including documentation of lab-test 
findings from the charts, BP measurements, and assessment of albuminuria and urine glucose 
in spot samples (Fig. 1).  
 
Sample and study participation 
 
An estimated total of 66,920 patients attended the participating practices (mean number of 
patients per doctor: 35). Because of logistical problems resulting from high patient load, 53% 
of participating doctors were unable to successfully screen all eligible patients. Thus, only a 
total of 51,905 questionnaires were distributed to patients attending the practice, of which 
46,129 were evaluable for further analyses (reasons for non-inclusion: refusal or withdrawal 
of consent, only sketchy information, etc.). In 1004 cases (2.2%), patient and physician 
questionnaires could not be matched. A set of analyses was run, using all available 
information, comparing the complete with the incomplete cases and the completers with the 
patients refusing participation. We found that the results did not vary across the number of 
valid questionnaires per primary care setting, and thus there was no evidence for bias.  
In 1576 (3.5%) cases, physicians failed to provide sufficient clinical information on 
hypertension or diabetes, and the present analysis was based on those 43,549 cases for which 
a valid clinical diagnosis for hypertension and diabetes was provided (either yes or no). In this 
sample, 17,485 (40.1%) were rated as hypertensive: 2702 (6.2%) as borderline cases, 12,286 
(28.2%) as having mild to moderate, and 2497 (5.7%) as having severe to extremely severe 
hypertension.  
 
Instruments 
 
The prestudy questionnaires served to collect information on participating physicians’ profiles 
(education and specialization), practice setting, and physicians’ attitudes and perceptions 
toward guidelines and programs for diabetes and hypertension management. The patients’ 
questionnaires were used to collect data on a variety of variables including biosocial 
characteristics, quality of life measures, life-style and behavioral risk factors, health status, 
and details on hypertension and diabetes history – and treatment, if applicable. The doctor’s 
clinical assessment of each individual patient by a standardized doctor’s questionnaire 
included rating of the current presence of hypertension and diabetes using the Clinical Global 
Impression Scale (CGI: not present, borderline, mild/ moderate, severe/extreme) [13] and 
indicating the presence or absence of 22 predefined somatic and mental disorders. Apart from 
hypertension, particular focus in the study was on diagnosis and treatment of diabetes.  
 
Diagnostic conventions 
 
The present analysis was exclusively based on the physicians’ clinical diagnoses of 
hypertension, diabetes, nephropathy and CHD. A comparison between the clinical 
hypertension diagnoses and the measured blood pressure values was the subject of another 
analysis [14]. Physician-rated borderline cases were included in accordance with the JNC-VI 
[15] and ICH-WHO [16] criteria, which also subsume these cases under mild hypertension. In 
diabetes, the situation is similar, since at diagnosis the disease has been present for several 
years, and already in early stages complications may occur [17].   
For the detection of albuminuria in a spot urine sample, the semi-quantitative dipstick Micral-
Test II (Boehringer Mannheim, Germany) was used [18], as it has proven useful in a primary 
care setting [19]. However, the diagnosis “nephropathy” was again a clinical one assigned by 
the treating physician. Body weight and height information were taken from the patient 
questionnaire. Body mass index (kg/m2) was calculated from these self-reported data and 
classified according to international conventions [20].  
The prescription information on antihypertensive drug classes for each patient was obtained 
from the physician questionnaire, using the following categories: none; ACE inhibitor, alpha 
blocker, AT1 receptor antagonist, b-blocker, calcium channel blocker, diuretic, other (such as 
centrally acting drug: reserpine, hydralazine, etc.). No information on non-proprietary names, 
brand names or dosages was collected.  
 
Statistical analyses 
 
Cross tables, frequency distributions and descriptive statistics were used to compare the 
distributions of variables among all categories. Differences in hypertension prevalence were 
quantified with odds ratios (ORs) estimated from logistic regressions [21] while adjusted for 
age group, sex and gender * age group and calculating robust confidence intervals for 
observations clustered within primary care settings [22]. Significance was assessed at the 
P=0.05 level. All analyses were conducted using the Stata 8 software package (Stata 
Corporation, College Station, TX USA 2003).  
 
 
Results 
 
Sample characteristics and drug treatment rates 
 
Table 1 summarizes selected sociodemographic and clinical baseline characteristics of the 
total of hypertensive patients, and – in order to display variability of characteristics of an 
important subgroup – of hypertensive patients with concomitant diabetes compared with 
hypertensive patients without diabetes. Typically, for primary care settings, a large proportion 
of these patients were of older age (mean 63.2 years; proportion aged 60 years or above: 
42%). Consistent with high age, the mean time since first diagnosis of hypertension was about 
4 years. Among diabetics with hypertension, males and older patients were overrepresented, 
had a slightly higher weight, and a higher number of additional diagnoses. In terms of mean 
systolic and diastolic BP, the groups were similar, i.e., had the same control status.  
Of all hypertensive patients (n=17,485), 1647 (9.4%) received no treatment at all, 1191 
(6.8%) received non-pharmacological measures only, 5791 (33.1%) antihypertensive drug 
therapy only and 8856 (50.7%) both antihypertensive drug therapy and non-pharmacological 
measures.  
The drug classes most frequently prescribed were in declining order, ACE inhibitors in 7126 
patients (40.8%), b-blockers in 6304 (36.1%), diuretics in 5546 (31.7%), calcium channel 
blockers in 3903 (22.3%), AT 1 receptor antagonists in 2470 (14.1%), „other“ 
antihypertensives in 763 (4.4%) and alpha-receptor blockers in 494 (2.8%) (Fig. 2).  
 
Prescription frequencies by age and gender 
 
Hypertensive patients aged 16–40 years received antihypertensive drug therapy only in 
57.4%, patients aged 41–60 years in 79.6% and those aged over 60 years in 87.7%. For all 
drug classes, a clear and significant association between age and the rate of prescriptions was 
found, with the exception of b-blockers or „other antihypertensives“, respectively.   
Figure 2 displays the prescription frequency of the various drug classes in males and females 
by age group. While there were no differences between genders in the overall probability of 
receiving drug treatment, certain gender specific differences in treatment patterns were 
evident. The figure indicates the following major differences: females in all age groups 
received ACE inhibitors, those in the 41- to 60-year-old group received alpha blockers and 
calcium channel blockers, and those in the above 60-year-old group received b-blockers less 
frequently. Conversely, females aged 16–40 years received b-blockers much more frequently 
than males in the same age group. After adjustment for age, these differences remained 
significant at the P<0.05 level for ACE inhibitors in all age groups [16–40 years: OR 0.5, 
(95% CI: 0.4;0.8); 41–60 years: OR: 0.8 (95% CI: 0.7;0.8); >60 years: 0.9 (95% CI: 0.8;0.9)], 
for alpha blockers only in the >60-year-old group [OR: 0.6 (95% CI: 0.5;0.7)], for calcium 
channel blockers in the 41- to 60-year olds: [OR: 0.8 (95% CI: 0.7;0.9)], and for b-blockers 
only in the 16- to 40-year olds [OR: 1.6 (95% CI: 1.2;2.1)].  
Concerning the use of combination therapy, there were no relevant differences between 
genders, with the exception of treatment with four or more drugs, which was less frequent in 
women than in men [OR: 0.8 (95% CI:0.6; 0.9)].  
 
 
Prescription frequencies according to concomitant disease 
 
Table 2 displays the number of antihypertensive drugs and the prescription rates of the 
individual classes by concomitant disease. Among patients with the diagnosis hypertension 
alone, the proportion of treated patients was 79.3%, among those with hypertension and 
diabetes it was 87.8%, among those with hypertension and nephropathy 88.3%, and among 
those with hypertension and CHD 93.1%.  
In comparison with hypertension „alone“ (i.e., without concomitant diabetes, nephropathy or 
CHD), patients with these co-morbidities had (1) a higher probability of receiving any drug 
treatment, (2) a higher probability of receiving, in particular, ACE inhibitors, diuretics, and 
calcium channel blockers, and (3) as indicated in the lower part of the table, a higher 
likelihood of receiving multiple drug prescriptions at the same time; thus, an increased 
treatment intensity. As can be derived from the ORs, these differences remain largely 
significant even after adjustment for age and gender.  
 
Prescription frequencies by physician characteristics and factors 
 
In addition to patient factors above, we also investigated certain physician characteristics that 
might have influence on drug treatment patterns. For example, in Germany, in certain settings 
or states (e.g., in Saxony) local guidelines exist that have particularly stringent treatment 
goals. Therefore, we investigated regional effects. There were no significant and pronounced 
differences in prescription patterns (defined as 0.66‡ORs‡1.5, P<0.05) in different settings 
(e.g., rural area vs major city; federal states).  
Among the participating physicians, 77% were GPs and 23% physicians for internal medicine 
in general practice. They prescribed anti-hypertensive drugs in a similar frequency (83.6% 
and 84.9%). No differences were found between their use of combination therapy and the 
individual drug classes, respectively.  
Of physicians, 31.7% reported following guidelines (German Hypertension League) when 
treating antihypertensive patients. However, the prescription pattern between these physicians 
and those not reporting following guidelines was marginal (differences in proportions in the 
various drug classes was about 2%).  
 
 
Discussion 
 
Data on drug utilization linked to routine diagnoses in primary care are scarce. These data, 
however, are of importance in view of the fact that the prevalence of hypertension in this 
setting was very high (40.1% of all patients in this study). The large majority of all 
hypertensive patients received drug treatment, and, despite these efforts, control rates were 
poor. In our sample, 70.6% of all hypertensive patients were not controlled and mean BP 
levels were 144.5/84.5 mmHg. This was considerably higher than mean BP values sampled 
from general population registries in Germany (136/ 83 mmHg in individuals aged 18–79 
years) [6, 23].  
The main outcomes of our study were: (1) Treatment rates depended on age: young 
hypertensive patients (16–40 years) compared with the older age groups were substantially 
less aggressively treated (low rate of drug treatment; if treated, mostly with monotherapy). (2) 
There were only limited gender differences. (3) Treatment intensity increased when 
concomitant diseases were present, while there were only minor changes in preferences of the 
various drug classes. (4) Selected physician variables did not influence drug prescribing.  
When interpreting the results of our study, certain limitations have to be taken into account. 
First, because of the cross-sectional design, there was no assessment whether the present 
therapy was the initial one (first line) or whether it replaced (switch) or amended (add-on) the 
original one. Therefore, no information about the treatment strategies over time can be 
provided. The design also did not allow determination of causal relationships. Third, as the 
study was performed on two half days (morning), selection bias with underrepresentation of 
employed patients cannot be excluded. Fourth, the results apply for typical primary care 
patients. Cases with severe forms of morbidity that were treated by specialists (e.g., certain 
hypertensive patients with CHD treated by a cardiologist) were not covered.  
Having these limitations in mind, treatment pattern with antihypertensive drugs appeared 
relatively uniform. Treatment intensity (as indicated by number of prescriptions) increased 
with age, and there were no major differences between genders, with few exceptions which 
are hard to explain. For example it is unclear why younger women received substantially 
more b-blockers than their male peers, and why this difference disappeared in the higher age 
groups. Did physicians make use of the additional psychotropic effects of b-blockers here or 
was it a precaution in women of childbearing age? In addition, a lower proportion of women 
received ACE inhibitors, while there were no major differences in the concomitant diseases. 
Importantly, treatment was intensified only (regarding proportion of treated patients, and/or 
number of drugs per patient) after complications had occurred. The broad armamentarium of 
drug treatment options seemed to be applied preferably at a later age and in patients with co-
morbidites. Secondary prevention rather than primary prevention of complications seemed to 
prevail in primary care.  
The 1999 ISH/WHO guidelines, which were widely disseminated during the time of the 
study, recommended „all available drug classes for the initiation and maintenance for 
antihypertensive therapy“ (i.e., diuretics, b-blockers, calcium channel blockers, ACE 
inhibitors, alpha blockers and AT1 receptor antagonists), but indicated that the choice of 
drugs is influenced by many factors such as socio-economic, cardiovascular risk factors, co-
existing diseases, patient responses, interactions, and strength of evidence. According to our 
data, it is likely that those differential considerations are applied in a limited manner. For 
example, age was a compelling indication for the selection of diuretics [16], and indeed it was 
prescribed more frequently in elders; however, to a smaller extent than calcium channel 
blockers, for example.  
The uniform use of antihypertensive drugs is striking when analyzing subgroups of patients 
with certain concomitant diseases, which should, according to acknowledged guidelines, 
trigger the selection of certain drug classes. For example, in nephropathy, ACE inhibitors or 
AT1 receptor antagonists should be preferred, but physicians used ACE inhibitors only in 
47.5% and AT1 receptor antagonists in 15.3%. In CHD patients with hypertension, which 
have a compelling indication for b-blockers and calcium channel blockers [16] the greatest 
increase in drug use compared to hypertension alone was for ACE inhibitors and diuretics.  
In this respect, it has been highlighted that the co-existence of diabetes and hypertension is 
important, as they are multiplicative risk factors for macrovascular and microvascular disease, 
resulting in increased rates of cardiac deaths, CHD, congestive heart failure and peripheral 
vascular disease [24, 25]. A hypertensive diabetic carries an approximately fourfold risk of 
mortality and morbidity in comparison with a non-hypertensive, non-diabetic individual. 
According to the ISH/ WHO guidelines, the concomitant presence of hypertension –  of any 
grade – and diabetes renders an individual to be a „high risk“ patient with a probability of 
experiencing a cardiovascular event of 20–30% in the next 10 years [16]. By the same token, 
several studies have impressively shown that BP lowering in diabetic patients leads to a 
considerably stronger risk reduction than in non-diabetics (HOT [26], STOP-2 [27], UKPDS 
[28]). This high risk is only partly considered when it comes to drug treatment. The treatment 
rates of hypertensive diabetics were somewhat higher than in patients with hypertension alone 
(87.8% vs 79.3%), and they were treated more often with combination therapy. Physicians in 
our study preferred ACE inhibitors and diuretics, which is according to current knowledge 
[29], however, did not apply b-blockers (which would address the high cardiac risk of 
diabetics) or AT1 receptor antagonists (effective in diabetic nephropathy) more frequently. 
Control rates in this group were astonishingly poor, and the need for aggressive therapy to 
reach the low target pressure of <130/85 mmHg was certainly not met [30].  
Interestingly, also „old“ drugs (such as reserpine, hydralazine, etc. categorized as „other anti-
hypertensive drugs“ in our study) were still in frequent use, despite the fact they were not 
recommended in clinical guidelines. The same was true for alpha blockers. The alpha blocker 
arm of the ALLHAT study was stopped because of an increase in cases of new-onset heart 
failure in patients assigned to the alpha blocker [31]. While this could merely represent 
unmasking of heart failure in patients previously treated with an ACE inhibitor or a diuretic, 
still the benefit of such treatment is questionable.  
A broad range of physician characteristics was investigated and was found to have only 
marginal effects on antihypertensive drug prescription behavior. For example, it was 
interesting to note that no important differences in prescribing occurred between general 
practitioners and internists. If one would have expected differences, e.g., due to differences in 
training, they might have vanished due to comparable work setting in daily practice, or 
common continuous medical education activities. Indeed hypertension treatment is one of 
those medical areas in which generalists and specialists provide care of equivalent quality 
[32]. It was surprising at first glance that no differences, too, were found when comparing 
physicians reporting adhering to guidelines compared with those who did not. However, the 
limited impact of guidelines is well known in a variety of medical fields, and has also been 
acknowledged in the WHO/ ISH 1999 hypertension guidelines („words without action“) [16].  
What might be the underlying reasons for the reluctance of physicians to treat hypertension 
aggressively enough? A variety of factors might explain this; for example the expectation in 
the management of younger patients that life style change or other non-pharmacological 
treatment may be sufficient [33], and in elderly the fear of doing harm by applying too-
intensive treatment [10, 34].  
Reasons for the relative uniformity of drug treatment – particularly evident when looking at 
the prescription patterns in subsets of patients with diabetes, nephropathy, or CHD – however, 
include the aspect that recommendations for optimal pharmacological treatment of 
hypertensive patients have been subject of debate, thus often not being perceived to be a real 
guidance for clinicians. Three examples may illustrate this: the controversy about potential 
harm of calcium channel blockers in increasing myocardial infarction [35], the one about 
usefulness of diuretics and b-blockers in hypertensive diabetics due to their potentially 
untoward effects [36], and the current one about the implications of the ALLHAT study [37]. 
Clinical inertia [38] on the side of physicians might well result from these experiences.    
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